EXCISION BIOTHERAPEUTICS
🇺🇸United States
Excision BioTherapeutics Showcases Promising CRISPR-Based Therapies for HBV and HSV at ASGCT 2025
Excision BioTherapeutics presented new data from its CRISPR-based therapies targeting hepatitis B virus (EBT-107) and herpes simplex virus keratitis (EBT-104) at the ASGCT 2025 Annual Meeting in New Orleans.
Gene Therapy and Gene Editing Show Promise in HIV Treatment
Excision BioTherapeutics' EBT-101, a CRISPR-based gene editing therapy, demonstrates safety and temporary HIV infection suppression in early trials.
CRISPR Technology Shows Promise Across Diverse Clinical Applications
CRISPR-Cas9 gene editing has achieved a significant milestone with FDA approval of Casgevy for sickle cell disease and transfusion-dependent beta thalassemia.
© Copyright 2025. All Rights Reserved by MedPath